Clinical trials: Aetiology
Diabetic Chronic Kidney Disease
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
A phase 2b, placebo-controlled, randomized, double-blind, multi-center study of GCS-100 in patients with chronic kidney disease caused by diabetes.
- Trial name
- NCT02312050
- Testing
- GCS-100
- Where
- 8 sites in United States
- Volunteers
- 375 people
- Sponsor
- La Jolla Pharmaceutical Company
Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
- Trial name
- NCT00041795
- Testing
- leteprinim potassium (Neotrofin)
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- NeoTherapeutics
Fever, Respiratory Tract Infections
Diagnostic Accuracy of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients
This is a prospective clinical validation study of a novel regulatory approved (CE-IVD) diagnostic assay called ImmunoXpert™ that will enroll 1222 pediatric patients.
- Trial name
- AutoPilot (NCT03052088)
- Where
- 2 sites in Germany, Italy
- Volunteers
- 1,140 people
- Sponsor
- MeMed Diagnostics Ltd.
Aspergillosis, Candidiasis
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
The objective of this study is to evaluate the safety and efficacy of intravenous micafungin for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.
- Trial name
- NCT02646800
- Testing
- Micafungin
- Where
- 16 sites in China
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma China, Inc.
Lung Injury
Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious…
- Trial name
- NCT06416709
- Testing
- mesenchymal stem cells, saline
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cell Energy Life Sciences Group Co. LTD
Nutritional Status
Nutritional Status of Cerebral Palsy Patients in Turkey
This is a single visit, non-interventional, cross sectional study about risk factors, etiology, nutritional status and feeding methods in CP patients.
- Trial name
- NCT02589704
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 1,123 people
- Sponsor
- Abbott Nutrition
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or…
- Trial name
- PATTERN (NCT03992404)
- Testing
- NT 201
- Where
- 71 sites in United States, Belgium and 13 more
- Volunteers
- 603 people
- Sponsor
- Merz Pharmaceuticals GmbH
X-Linked Retinitis Pigmentosa
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
- Trial name
- NCT06333249
- Testing
- rAAV2tYF-GRK1-RPGR
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Beacon Therapeutics
Tinea Pedis
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes.
- Trial name
- NCT07668999
- Testing
- ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Glaucoma, Neovascular
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG).
- Trial name
- VENERA (NCT03639675)
- Testing
- Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs
- Where
- 7 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Leber Congenital Amaurosis, LCA
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Primary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate…
- Conditions
- Leber Congenital Amaurosis, LCA, LCA1
- Trial name
- NCT03920007
- Testing
- ATSN-101, ATSN-101 Diluent Solution, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Atsena Therapeutics Inc.
Acquired Immunodeficiency Syndrome, Anemia
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo in AIDS patients for the treatment of anemia that is a result of the disease or a result of zidovudine (AZT) treatment for AIDS.
- Trial name
- NCT00270270
- Testing
- epoetin alfa
- Volunteers
- 63 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fibroses, Pulmonary
Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
- Trial name
- NCT04645368
- Testing
- bovhyaluronidase azoxymer
- Where
- 15 sites in Russia
- Volunteers
- 160 people
- Sponsor
- NPO Petrovax
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Malaria
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
- Trial name
- NCT00866619
- Testing
- Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine
- Where
- 10 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 15,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three…
- Trial name
- NCT03130465
- Where
- 67 sites in France, Germany and 2 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion cancer.
- Trial name
- NCT04945330
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Hip Pain Etiology Unknown
Navigator vs Standard Needle Injection for Hip
The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a…
- Trial name
- NCT02066844
- Testing
- Celestone, Lidocaine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cartiva, Inc.
Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and…
- Trial name
- NCT05349019
- Testing
- Observational
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Escape Bio, Inc.